2023 World Conference on Lung Cancer (Posters)-EP12.01. Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC

EP12.01. Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC - PDF(Abstract)

Back to course

Pdf Summary

A clinical advances curriculum was developed in 2021 to address the knowledge gaps of oncologists regarding the management of EGFR exon 20 insertion mutated NSCLC and EGFR TKI-resistant NSCLC. The objective of this study was to assess the impact of this educational curriculum on oncologists' knowledge, competence, and confidence. <br /><br />The curriculum consisted of 6 online CME activities covering various educational gaps in the management of EGFR exon 20 insertion mutated NSCLC and EGFR TKI-resistant NSCLC. Repeat pairs design was used to assess the educational impact, with participants being asked pre-education and post-education knowledge, competence, and confidence questions. The data was collected from January 2021 to February 2022, and statistical significance was determined using McNemar's test.<br /><br />A total of 4,330 healthcare professionals participated in the activities, with 2,439 of them being oncologists. The assessment questions and outcomes were divided into 7 themes. The results showed that there was a relative increase in correct responses and confidence across 5 out of the 7 themes after education. These themes included diagnosing EGFR exon 20 insertion mutations in advanced NSCLC, clinical implications of EGFR exon 20 insertion mutations, efficacy and safety data for therapies targeting EGFR exon 20 insertion mutated NSCLC, diagnosing EGFR TKI resistance in advanced NSCLC, and efficacy data for therapies targeting EGFR TKI-resistant NSCLC.<br /><br />The study concluded that the clinical advances curriculum had a positive impact on the knowledge, competence, and confidence of oncologists in these specific areas. However, due to the rapidly developing field, further education will be necessary to keep clinicians updated on the latest data and best practices.

Asset Subtitle

Nabil Dorkhom

Meta Tag

Speaker Nabil Dorkhom

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

clinical advances curriculum

oncologists

EGFR exon 20 insertion mutated NSCLC

EGFR TKI-resistant NSCLC

knowledge gaps

competence

confidence

online CME activities

diagnosing

efficacy data